OP

OPKO Health, Inc.

OPKHealthcareNASDAQ

Diagnostics & Research · Last scanned Sep 8, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$606.9M
-14.9% YoY
Net Income
-$225.7M
-324.0% YoY
EBITDA
-$41.3M
-130.5% YoY
Free Cash Flow
$54.8M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3CONFIRMED RSI OverboughtRSI 82.2, above 70, stock may be overbought
Sep 2 RSI OverboughtRSI 72.4, above 70, stock may be overbought
About OPKO Health, Inc.

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. With a market capitalization of $1.22B, it sits in small-cap territory. The company operates in two segments, Pharmaceutical and Diagnostics.

Where OPK stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, OPK finished 32.03% above its 150-day moving average ($1.28) and 31.01% above its 200-day moving average ($1.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is OPK overbought or oversold?

At the September 3, 2026 close, OPK's RSI(14) was 82.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.22B
Fwd P/E-5.96
EPS$-0.07
Beta1.50
52W Change+16.3%
ROE-5.9%
Analysis

The company holds $300.8M in cash, though total debt stands at $398.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $54.8M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -5.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $1.00B (2022) to $606.9M (2025), a 40% decline worth watching.

OPKO Health, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence OPKO Health, Inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms